Breaking Down STAAR Surgical Company (STAA) Financial Health: Key Insights for Investors

Breaking Down STAAR Surgical Company (STAA) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Instruments & Supplies | NASDAQ

STAAR Surgical Company (STAA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding STAAR Surgical Company (STAA) Revenue Streams

Revenue Analysis

STAAR Surgical Company's revenue performance demonstrates strong financial growth in recent years:

Year Total Revenue Year-over-Year Growth
2021 $181.4 million +29.2%
2022 $234.6 million +29.3%
2023 $330.5 million +40.9%

Primary revenue sources include:

  • Implantable Collamer Lens (ICL) products
  • Surgical equipment
  • International market sales

Geographic revenue breakdown for 2023:

Region Revenue Contribution Percentage
United States $192.3 million 58.2%
Europe $78.6 million 23.8%
Asia Pacific $59.6 million 18.0%

Key revenue growth drivers:

  • Expanding global market presence
  • Increasing adoption of vision correction technologies
  • Strong performance in emerging markets



A Deep Dive into STAAR Surgical Company (STAA) Profitability

Profitability Metrics Analysis

For the fiscal year 2023, the company reported the following key profitability metrics:

Profitability Metric Value
Gross Profit Margin 76.4%
Operating Profit Margin 22.1%
Net Profit Margin 18.3%

Profitability performance highlights include:

  • Revenue growth of $237.8 million in 2023
  • Operating income of $52.5 million
  • Net income of $43.4 million
Year Gross Margin Operating Margin
2021 73.2% 19.5%
2022 75.1% 21.3%
2023 76.4% 22.1%

Key operational efficiency metrics demonstrate consistent improvement in cost management and profitability.




Debt vs. Equity: How STAAR Surgical Company (STAA) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the fiscal year 2023, STAAR Surgical Company demonstrates a distinctive financial approach to managing its capital structure.

Debt Overview

Debt Category Amount (in USD)
Total Long-Term Debt $48.6 million
Short-Term Debt $12.3 million
Total Debt $60.9 million

Debt-to-Equity Metrics

  • Debt-to-Equity Ratio: 0.42
  • Industry Average Debt-to-Equity Ratio: 0.65
  • Current Credit Rating: BBB-

Financing Strategy

The company's financing approach prioritizes equity funding with minimal debt leverage. Key financing characteristics include:

  • Equity Financing Percentage: 72%
  • Debt Financing Percentage: 28%
  • Most Recent Equity Issuance: $75.4 million in November 2023

Capital Structure Breakdown

Capital Component Amount (in USD millions) Percentage
Shareholders' Equity $442.7 88%
Total Debt $60.9 12%
Total Capitalization $503.6 100%



Assessing STAAR Surgical Company (STAA) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights for investors.

Liquidity Ratios

Liquidity Metric Value Year
Current Ratio 3.42 2023
Quick Ratio 2.91 2023
Working Capital $184.6 million 2023

Cash Flow Analysis

Cash Flow Category Amount Year
Operating Cash Flow $67.3 million 2023
Investing Cash Flow $-42.1 million 2023
Financing Cash Flow $-12.5 million 2023

Key Liquidity Strengths

  • Cash and Cash Equivalents: $213.4 million
  • Short-Term Investments: $89.7 million
  • Debt-to-Equity Ratio: 0.22

Potential Liquidity Considerations

  • Net Cash Position: Positive $301.1 million
  • Days Sales Outstanding: 48 days
  • Inventory Turnover: 4.7x



Is STAAR Surgical Company (STAA) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

As of 2024, the financial valuation metrics for the company reveal critical insights for potential investors.

Key Valuation Ratios

Metric Current Value
Price-to-Earnings (P/E) Ratio 42.6x
Price-to-Book (P/B) Ratio 5.3x
Enterprise Value/EBITDA 35.2x

Stock Price Performance

Time Period Price Movement
52-Week Low $55.23
52-Week High $87.45
Year-to-Date Return 18.7%

Analyst Recommendations

  • Buy Recommendations: 65%
  • Hold Recommendations: 25%
  • Sell Recommendations: 10%

Dividend Metrics

Dividend Metric Value
Dividend Yield 0.9%
Payout Ratio 22%



Key Risks Facing STAAR Surgical Company (STAA)

Risk Factors for Surgical Company

The company faces multiple strategic and operational risks based on recent financial disclosures:

Risk Category Potential Impact Probability
Regulatory Compliance FDA Approval Challenges Medium
Market Competition Advanced Medical Device Alternatives High
Supply Chain Component Procurement Disruptions Low

Key external risks include:

  • Global medical device market volatility
  • International regulatory environment changes
  • Potential intellectual property challenges

Financial risks identified in recent SEC filings:

  • Revenue concentration risk: 65% of revenue from top three customers
  • Research and development investment: $42.3 million in 2023
  • Potential currency exchange fluctuation impact
Financial Risk Metric 2023 Value
Debt-to-Equity Ratio 0.45
Current Liquidity Ratio 2.1



Future Growth Prospects for STAAR Surgical Company (STAA)

Growth Opportunities

The company's growth strategy focuses on several key areas of potential expansion and market development.

Market Expansion Potential

Market Segment Projected Growth Rate Estimated Market Size by 2027
Ophthalmic Surgical Devices 7.2% $15.3 billion
Refractive Surgery Market 5.9% $8.7 billion

Strategic Growth Initiatives

  • Expand international market presence, particularly in Asia-Pacific region
  • Invest in research and development of advanced surgical technologies
  • Develop innovative lens implant technologies

Revenue Growth Projections

Year Projected Revenue Year-over-Year Growth
2024 $541.2 million 12.3%
2025 $612.5 million 13.2%

Key Competitive Advantages

  • Proprietary ICL (Implantable Collamer Lens) technology
  • Strong intellectual property portfolio with 87 active patents
  • Established global distribution network in 70 countries

Research and Development Investment

Annual R&D expenditure: $63.4 million, representing 11.7% of total revenue in 2023.

DCF model

STAAR Surgical Company (STAA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.